Bogart Wealth LLC Has $8.96 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bogart Wealth LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 15.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,259 shares of the pharmaceutical company's stock after acquiring an additional 3,031 shares during the quarter. Bogart Wealth LLC's holdings in Vertex Pharmaceuticals were worth $8,964,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. State Street Corp grew its holdings in shares of Vertex Pharmaceuticals by 0.8% during the third quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company's stock worth $5,495,501,000 after buying an additional 90,173 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company's stock worth $2,581,373,000 after buying an additional 851,054 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Vertex Pharmaceuticals by 17.2% during the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock worth $2,231,858,000 after buying an additional 704,421 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Vertex Pharmaceuticals by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company's stock worth $1,351,385,000 after buying an additional 159,693 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Vertex Pharmaceuticals by 4.1% during the third quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company's stock worth $1,170,506,000 after buying an additional 100,114 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock traded up $3.11 during mid-day trading on Tuesday, reaching $462.11. 1,405,218 shares of the company were exchanged, compared to its average volume of 1,546,074. The company has a fifty day simple moving average of $435.39 and a 200-day simple moving average of $460.67. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The firm has a market cap of $119.01 billion, a PE ratio of -232.22, a PEG ratio of 1.80 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.94 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Ourania Tatsis sold 310 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now owns 64,021 shares of the company's stock, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.20% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and increased their price objective for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and increased their price target for the company from $408.00 to $424.00 in a research report on Tuesday, February 11th. UBS Group increased their price target on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Morgan Stanley increased their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 11th. Finally, StockNews.com cut Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 21st. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $505.57.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.